Night Manager Romance: Teddy’s Doomed Love Story
- *Warning: spoilers for the Night Manager season two episode four*
- The bullets sent flying were the least dramatic part of the shoot-out that brought The Night Manager's latest chapter to a close.
- Jonathan Pine (Tom Hiddleston) finally revealed his true self to Teddy Dos Santos (Diego Calva), to rescue an innocent teenager tricked into aiding the assassination of Alejandro Gualteros...
Add The Night Manager to your watchlist
*Warning: spoilers for the Night Manager season two episode four*
The bullets sent flying were the least dramatic part of the shoot-out that brought The Night Manager’s latest chapter to a close.
Jonathan Pine (Tom Hiddleston) finally revealed his true self to Teddy Dos Santos (Diego Calva), to rescue an innocent teenager tricked into aiding the assassination of Alejandro Gualteros (Alberto Ammann).
But the sequence didn’t play out like a typical double-cross, the likes of which spy fiction is filled with.The swelling music, teary eyes and anguished outburst made one thing clear: this was a matter of the heart.
Pine’s earlier flirtations with Teddy certainly hadn’t gone unnoticed (a gentle touch here, a stolen glance there), but even after last week’s steamy dance scene, it remained unclear whether the deep cover agent was just exploiting him.
Well,consider that case closed.
In contrast to Pine’s unhesitating brutality towards season 1 rivals Corky (Tom Hollander) and Freddie (David Avery), we can clearly see that he’s distraught to be raising his weapon against Teddy – despite having legitimate cause.
Both Hiddleston and Calva deserve high praise for this powerful stand-off, but especially the latter, who is dragged through a dizzying cycle of confusion, heartbreak and fury as Teddy wakes up to his deception.
It’s gut-wrenching enough to make you briefly forget who the ‘villain’ is in this scene, which is extraordinary given that one character just executed a public servant for no other reason than he couldn’t be bought.
To Calva’s credit, even in the grotesque inhumanity of that action, we can still see the dying embers of a soul in Teddy – which is perhaps what draws Pine to him as well. It begs the question: can he be redeemed for his many grave sins?
AI-Driven Drug Discovery Accelerates, but Challenges Remain
Artificial intelligence is dramatically reshaping pharmaceutical research, cutting progress times and costs, but experts caution that widespread adoption hinges on addressing data quality and regulatory hurdles. A report released today by the Biotechnology Innovation Organization (BIO) found that AI-driven drug discovery projects saw a 35% reduction in preclinical development time compared to conventional methods, and a 28% decrease in associated costs.
The BIO report, based on data from 57 pharmaceutical companies and research institutions, details the growing investment in AI. Total venture funding for AI-powered drug discovery reached $8.4 billion in 2025,a 150% increase from $3.36 billion in 2023, according to PitchBook data. This surge in funding is fueling the development of new AI platforms capable of identifying potential drug candidates, predicting clinical trial outcomes, and personalizing treatment plans.
Several companies are already seeing success. Recursion Pharmaceuticals, such as, reported a 40% success rate in identifying promising drug candidates using its AI-powered platform, compared to an industry average of around 10%. Exscientia, another key player, has three AI-designed drugs currently in clinical trials, including a potential treatment for obsessive-compulsive disorder.
Though, the path to widespread implementation isn’t without obstacles. A primary concern is the quality and accessibility of data. “AI algorithms are only as good as the data they’re trained on,” explains Dr. anya sharma, Chief Scientific Officer at the National Institutes of Health (NIH). “If the data is biased or incomplete, the results will be unreliable.” The NIH is currently investing $500 million in initiatives to improve data standardization and sharing across the research community.
Regulatory frameworks also need to evolve. The Food and Drug Administration (FDA) is actively working to establish guidelines for the use of AI in drug development, but a clear regulatory pathway is still lacking. According to an FDA statement released on January 15, 2026, the agency is prioritizing the development of “risk-based” regulations that will ensure the safety and efficacy of AI-designed drugs.
Despite these challenges, the potential benefits of AI in drug discovery are undeniable. Experts predict that AI could accelerate the development of treatments for diseases like Alzheimer’s, cancer, and infectious diseases, ultimately improving patient outcomes and extending lifespans.
Key Findings from the BIO Report:
- Preclinical Development Time Reduction: 35%
- Cost Reduction in Preclinical Development: 28%
- Venture Funding in 2025: $8.4 billion
- venture Funding Increase (2023-2025): 150%
- Recursion Pharmaceuticals Candidate Success Rate: 40%
- Industry Average Candidate Success Rate: 10%
Biotechnology Innovation Organization (BIO) Report